Medical Design Technology -
18 Jul 2016 16:15
News The diagnostic imaging study will administer MVT-2163 as a PET imaging agent for patients with pancreatic cancer. Contributed Author: MabVax Therapuetics Holdings Topics: Medical Diagnostics
Share this Article